TRYVIO nominated for the 2025 Prix Galien USA “Best Pharmaceutical Product”

Core Viewpoint - Idorsia Ltd's TRYVIO™ (aprocitentan) has been nominated for the "Best Pharmaceutical Product" category in the 2025 Prix Galien USA awards, highlighting its innovative approach to treating systemic hypertension [1][5]. Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific foundation [8][9]. - The company is headquartered near Basel, Switzerland, and has a dedicated team covering all disciplines from research to commercialization [9]. Product Information - TRYVIO™ is the first systemic hypertension treatment targeting a new pathway in over 30 years, functioning as a dual endothelin receptor antagonist (ERA) [3][7]. - It is indicated for use in combination with other antihypertensive drugs to lower blood pressure in adult patients inadequately controlled on existing therapies [3][7]. - TRYVIO™ has shown consistent blood pressure-lowering effects across various patient subgroups, including those with difficult-to-treat hypertension [4]. Health Impact - Hypertension affects an estimated 50% of adults in the US, with half of those patients not well controlled despite medication, leading to increased risks of cardiovascular events [4]. - The treatment of hypertension is critical as it is the number one modifiable risk factor for early morbidity and mortality [4]. Award Significance - The Prix Galien Award is recognized globally as a prestigious honor in biopharmaceutical research, akin to the Nobel Prize, celebrating innovations that improve human health [5].